Search Results - "Luebbe, Kristina"

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials by Denkert, Carsten, Seither, Fenja, Schneeweiss, Andreas, Link, Theresa, Blohmer, Jens-Uwe, Just, Marianne, Wimberger, Pauline, Forberger, Almuth, Tesch, Hans, Jackisch, Christian, Schmatloch, Sabine, Reinisch, Mattea, Solomayer, Erich F, Schmitt, Wolfgang D, Hanusch, Claus, Fasching, Peter A, Lübbe, Kristina, Solbach, Christine, Huober, Jens, Rhiem, Kerstin, Marmé, Frederik, Reimer, Toralf, Schmidt, Marcus, Sinn, Bruno V, Janni, Wolfgang, Stickeler, Elmar, Michel, Laura, Stötzer, Oliver, Hahnen, Eric, Furlanetto, Jenny, Seiler, Sabine, Nekljudova, Valentina, Untch, Michael, Loibl, Sibylle

“…The development of anti-HER2 antibody–drug conjugates opens new therapeutic options for patients with breast cancer, including patients with low expression of…”
Get full text

Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial by Schneeweiss, Andreas, Möbus, Volker, Tesch, Hans, Hanusch, Claus, Denkert, Carsten, Lübbe, Kristina, Huober, Jens, Klare, Peter, Kümmel, Sherko, Untch, Michael, Kast, Karin, Jackisch, Christian, Thomalla, Jörg, Ingold-Heppner, Barbara, Blohmer, Jens-Uwe, Rezai, Mahdi, Frank, Matthias, Engels, Knut, Rhiem, Kerstin, Fasching, Peter Andreas, Nekljudova, Valentina, von Minckwitz, Gunter, Loibl, Sibylle

“…GeparOcto compared efficacy and safety of two chemotherapy regimens in high-risk early breast cancer (BC): sequential treatment with intense dose-dense…”
Get full text

Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer by Schneeweiss, Andreas, Michel, Laura L., Möbus, Volker, Tesch, Hans, Klare, Peter, Hahnen, Eric, Denkert, Carsten, Kast, Karin, Pohl-Rescigno, Esther, Hanusch, Claus, Link, Theresa, Untch, Michael, Jackisch, Christian, Blohmer, Jens-Uwe, Fasching, Peter A., Solbach, Christine, Schmutzler, Rita K., Huober, Jens, Rhiem, Kerstin, Nekljudova, Valentina, Lübbe, Kristina, Loibl, Sibylle

“…GeparOcto demonstrated that pathological complete response (pCR) of intense dose-dense epirubicin, paclitaxel and cyclophosphamide (iddEPC) was comparable to…”
Get full text

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial by Müller, Volkmar, Gade, Stephan, Steinbach, Bettina, Loibl, Sibylle, von Minckwitz, Gunter, Untch, Michael, Schwedler, Kathrin, Lübbe, Kristina, Schem, Christian, Fasching, Peter A., Mau, Christine, Pantel, Klaus, Schwarzenbach, Heidi

“…Trastuzumab and lapatinib are established treatments for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer with different…”
Get full text

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer by Vergote, Ignace, Pérez-Fidalgo, Jose Alejandro, Hamilton, Erika Paige, Valabrega, Giorgio, Van Gorp, Toon, Sehouli, Jalid, Cibula, David, Levy, Tally, Welch, Stephen, Richardson, Debra L, Guerra, Eva M, Scambia, Giovanni, Henry, Stéphanie, Wimberger, Pauline, Miller, David S, Klat, Jaroslav, Martínez-Garcia, Jerónimo, Raspagliesi, Francesco, Pothuri, Bhavana, Romero, Ignacio, Bergamini, Alice, Slomovitz, Brian, Schochter, Fabienne, Høgdall, Estrid, Fariñas-Madrid, Lorena, Monk, Bradley J, Michel, Dayana, Kauffman, Michael G, Shacham, Sharon, Mirza, Mansoor Raza, Makker, Vicky

“…Selinexor inhibits exportin-1 (XPO1) resulting in nuclear accumulation of tumor suppressor proteins including p53 and has clinical activity in endometrial…”
Get full text

Association between pCR, TILs, and Ki-67 at baseline and after 2 weeks in patients with triple-negative breast cancer (TNBC) treated with atezolizumab and chemotherapy +/- a preceding atezolizumab monotherapy window: A translational analysis of the neoMono trial by Erber, Ramona, Kolberg, Hans-Christian, Schumacher, Johannes, Braun, Michael, Fasching, Peter A., Grischke, Eva-Maria, Schem, Christian, Lux, Michael Patrick, Deryal, Mustafa, Hoffmann, Oliver, Heinrich, Bernhard, Kunz, Georg, Luebbe, Kristina, Krabisch, Petra, Hartmann, Arndt, Raeth, Philip, Kasimir-Bauer, Sabine, Kolberg-Liedtke, Cornelia

“…595 Background: neoMono randomized patients (pts) with triple negative breast cancer (TNBC) to receive (Arm A) or not to receive (Arm B) 2-week Atezolizumab…”
Get full text

Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy by Furlanetto, Jenny, Möbus, Volker, Schneeweiss, Andreas, Rhiem, Kerstin, Tesch, Hans, Blohmer, Jens-Uwe, Lübbe, Kristina, Untch, Michael, Salat, Christoph, Huober, Jens, Klare, Peter, Schmutzler, Rita, Couch, Fergus J., Lederer, Bianca, Gerber, Bernd, Zahm, Dirk-Michael, Bauerfeind, Ingo, Nekljudova, Valentina, Hanusch, Claus, Jackisch, Christian, Link, Theresa, Hahnen, Eric, Loibl, Sibylle, Fasching, Peter A.

“…BRCA1 and BRCA2 play a central role in DNA repair. Therefore, patients harbouring germline (g) BRCA1/2 mutations (m) treated with chemotherapy might be at…”
Get full text

Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial by Pohl-Rescigno, Esther, Hauke, Jan, Loibl, Sibylle, Möbus, Volker, Denkert, Carsten, Fasching, Peter A, Kayali, Mohamad, Ernst, Corinna, Weber-Lassalle, Nana, Hanusch, Claus, Tesch, Hans, Müller, Volkmar, Altmüller, Janine, Thiele, Holger, Untch, Michael, Lübbe, Kristina, Nürnberg, Peter, Rhiem, Kerstin, Furlanetto, Jenny, Lederer, Bianca, Jackisch, Christian, Nekljudova, Valentina, Schmutzler, Rita K, Schneeweiss, Andreas, Hahnen, Eric

“…The GeparOcto randomized clinical trial compared the efficacy of 2 neoadjuvant breast cancer (BC) treatment regimens: sequential intense dose-dense epirubicin,…”
Get more information

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA) by Decker, Thomas, Lüdtke-Heckenkamp, Kerstin, Melnichuk, Luidmila, Hirmas, Nader, Lübbe, Kristina, Zahn, Mark-Oliver, Schmidt, Marcus, Denkert, Carsten, Lorenz, Ralf, Müller, Volkmar, Zahm, Dirk-Michael, Mundhenke, Christoph, Bauer, Stefan, Thill, Marc, Seropian, Peter, Filmann, Natalie, Loibl, Sibylle

“…This phase II study evaluated the impact of adding ribociclib to maintenance endocrine therapy (ET) treatment of physicians’ choice following the first…”
Get full text

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial by Gerber, Bernd, Schneeweiss, Andreas, Möbus, Volker, Golatta, Michael, Tesch, Hans, Krug, David, Hanusch, Claus, Denkert, Carsten, Lübbe, Kristina, Heil, Jörg, Huober, Jens, Ataseven, Beyhan, Klare, Peter, Hahn, Markus, Untch, Michael, Kast, Karin, Jackisch, Christian, Thomalla, Jörg, Seither, Fenja, Blohmer, Jens-Uwe, Rhiem, Kerstin, Fasching, Peter A, Nekljudova, Valentina, Loibl, Sibylle, Kühn, Thorsten

“…The conversion of initially histologically confirmed axillary lymph node-positive (pN+) to ypN0 after neoadjuvant systemic treatment (NAST) is an important…”
Get full text

Guideline adherence and clinical outcome in vulnerable and healthy breast cancer patients: Results of a prospective cross-sectional study in Germany by Kuehnle, Elna, Siggelkow, Wulf, Schrader, Iris, Luebbe, Kristina, Noeding, Stefanie, Moser, Alexander, John, Jutta, Noesselt, Thomas, Arfsten, Momme, Hillemanns, Peter, Dörk, Thilo, Park-Simon, Tjoung-Won

“…Abstract only e18132 Background: In 2003 the German Cancer Society and the German Society for Breast Disease introduced a number of Quality Indicators (QIs) to…”
Get full text

Prospective cross-sectional-study on influence of immigration background and education on breast cancer survival in a real-world setting by Kuehnle, Elna, Siggelkow, Wulf, Luebbe, Kristina, Schrader, Iris, Noeding, Stefanie, Noeding, Karl-Heinz, Noesselt, Thomas, Arfsten, Momme, Busch, Christoph, Meier, Regina, Hillemanns, Peter, Dörk, Thilo, Park-Simon, Tjoung-Won

“…Abstract only…”
Get full text

Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial by Rüger, Alexandra Maria, Schneeweiss, Andreas, Seiler, Sabine, Tesch, Hans, van Mackelenbergh, Marion, Marmé, Frederik, Lübbe, Kristina, Sinn, Bruno, Karn, Thomas, Stickeler, Elmar, Müller, Volkmar, Schem, Christian, Denkert, Carsten, Fasching, Peter A, Nekljudova, Valentina, Garfias-Macedo, Tania, Hasenfuß, Gerd, Haverkamp, Wilhelm, Loibl, Sibylle, von Haehling, Stephan

“…Background Patients with breast cancer can be affected by cardiotoxic reactions through cancer therapies. Cardiac biomarkers, like NT-proBNP (N-terminal…”
Get full text

Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344) by Pohl-Rescigno, Esther, Hauke, Jan, Rhiem, Kerstin, Möbus, Volker, Furlanetto, Jenny, Denkert, Carsten, Fasching, Peter A., Hanusch, Claus, Tesch, Hans, Weber-Lassalle, Nana, Müller, Volkmar, Untch, Michael, Luebbe, Kristina, Lederer, Bianca, Jackisch, Christian, Nekljudova, Valentina, Schmutzler, Rita K., Loibl, Sibylle, Schneeweiss, Andreas, Hahnen, Eric

“…Abstract only 573 Background: GeparOcto compared the efficacy of two neoadjuvant treatment (NAT) regimens in high-risk early breast cancer (BC): Sequential…”
Get full text

A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy in patients with hormone receptor positive/HER2-negative metastatic breast cancer in a real world setting by Loibl, Sibylle, Barinoff, Jana, Seiler, Sabine, Decker, Thomas, Denkert, Carsten, Luebbe, Kristina, Furlanetto, Jenny, Mueller, Volkmar, Mundhenke, Christoph, Schmidt, Marcus, von Minckwitz, Gunter, Uhlig, Mathias, Burchardi, Nicole, Thill, Marc

“…Abstract only TPS1115 Background: Although endocrine based therapy is recommended as first-line treatment in metastatic breast cancer (MBC) in patients with an…”
Get full text

First Prospective Cross-Sectional Study on the Impact of Immigration Background and Education in Early Detection of Breast Cancer by Kuehnle, Elna, Siggelkow, Wulf, Luebbe, Kristina, Schrader, Iris, Noeding, Karl-Heinz, Noeding, Stefanie, Noesselt, Thomas, Hillemanns, Peter, Dörk, Thilo, Park-Simon, Tjoung-Won

“…Background: Although immigrant health is an important issue in national health policy, there is a serious shortage of data in many countries. Most studies lack…”
Get full text

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA) by Bischoff, Joachim, Barinoff, Jana, Mundhenke, Christoph, Bauerschlag, Dirk O, Costa, Serban-Dan, Herr, Daniel, Lübbe, Kristina, Marmé, Frederik, Maass, Nicolai, von Minckwitz, Gunter, Grischke, Eva-Maria, Müller, Volkmar, Schmidt, Marcus, Gerber, Bernd, Kümmel, Sherko, Schumacher, Claudia, Krabisch, Petra, Seiler, Sabine, Thill, Marc, Nekljudova, Valentina, Loibl, Sibylle

“…The E-VITA study evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER-2-positive…”
Get full text

A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto) by Schneeweiss, Andreas, Moebus, Volker, Tesch, Hans, Hanusch, Claus, Denkert, Carsten, Luebbe, Kristina, Huober, Jens Bodo, Klare, Peter, Kummel, Sherko, Untch, Michael, Kast, Karin, Jackisch, Christian, Thomalla, Jörg, Ingold Heppner, Barbara, Blohmer, Jens U., Rezai, Mahdi, Frank, Matthias, Nekljudova, Valentina, Von Minckwitz, Gunter, Loibl, Sibylle

“…Abstract only 518 Background: The sequential use of intense does-dense (idd) epirubicin, paclitaxel, cyclophosphamide (EPC) and weekly paclitaxel/liposomal…”
Get full text

Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer by Lück, Hans-Joachim, Lübbe, Kristina, Reinisch, Mattea, Maass, Nicolai, Feisel-Schwickardi, Gabriele, Tomé, Oliver, Janni, Wolfgang, Aydogdu, Mustafa, Neunhöffer, Tanja, Ober, Angelika, Aktas, Bahriye, Park-Simon, Tjoung-Won, Schumacher, Claudia, Höffkes, Heinz-Gert, Illmer, Thomas, Wagner, Harald, Mehta, Keyur, von Minckwitz, Gunter, Nekljudova, Valentina, Loibl, Sibylle

“…Taxanes (T) plus bevacizumab (B) and taxanes plus capecitabine (X) showed better progression-free survival (PFS) compared to taxanes alone. Since…”
Get full text

Hormone receptor discordance between local and central pathology with RT-PCR analysis: Results from multicenter Phase III WSG-PlanB trial by Von Schumann, Raquel, Gluz, Oleg, Nitz, Ulrike, Clemens, Michael, Luebbe, Kristina, Aktas, Bahriye, Just, Marianne, Noesselt, Thomas, Henschen, Stephan, Hackmann, John, Lorenz-Salehi, Fatemeh, Freese, Kristin, Svedman, Christer, Kates, Ronald E., Kreipe, Hans Heinrich, Harbeck, Nadia, Liedtke, Cornelia

“…Abstract only…”
Get full text